Cooper C. Collins, MBA, serves as Managing Partner and CIO of MagnaSci Venture funds including advisory roles to many Pharmaceutical and Biotechnology companies. He is a founder of Pernix Therapeutics Holdings, Inc., (PTX: NASDAQ), a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic, and OTC products. Mr Collins served as President and CEO of Pernix from 2008 until May of 2013. During his career with Pernix, Mr. Collins worked in every capacity from sales representative to the executive level. While serving as CEO, Mr. Collins guided the Company to over an 800% increase in sales. In 2010, Mr. Collins was invited to ring the bell at the NYSE. At that time, he was the youngest CEO of a publicly traded pharmaceutical company in history.
Mr. Collins also serves as a Board Member, as Chairman of the Compensation Committee and Chairman of the Audit Committee for TherapeuticsMD, Inc., (TXMD: NASDAQ), a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. While serving on the board of TXMD Mr. Collins helped the Company grow its Market Capitalization by 80 times and helped the company sell its women’s health business to Mayne Pharma Group (MYX: ASX) Mr. Collins also serves on boards of privately owned companies in many sectors including defense, recycling, tech, entertainment, banking, healthcare, energy, and manufacturing.
Mr. Collins currently lives in the Houston area with his wife, Stacey, and their two children. The Collins’s philanthropic activities are heavily weighted in favor of charities for children and veterans, including participating as a board member of the Quick Response Foundation and as a board member of Curetivity.
